Kintegral Advisory LLC Sells 6,397 Shares of Biogen Inc. (NASDAQ:BIIB)

Kintegral Advisory LLC trimmed its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 32.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,038 shares of the biotechnology company's stock after selling 6,397 shares during the period. Kintegral Advisory LLC's holdings in Biogen were worth $1,784,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of BIIB. Signaturefd LLC increased its stake in shares of Biogen by 3.5% in the 4th quarter. Signaturefd LLC now owns 2,092 shares of the biotechnology company's stock valued at $320,000 after buying an additional 71 shares during the period. Israel Discount Bank of New York raised its holdings in shares of Biogen by 6.2% during the fourth quarter. Israel Discount Bank of New York now owns 1,405 shares of the biotechnology company's stock worth $215,000 after acquiring an additional 82 shares during the period. B. Riley Wealth Advisors Inc. raised its position in Biogen by 4.1% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 2,343 shares of the biotechnology company's stock valued at $358,000 after buying an additional 92 shares during the last quarter. Quent Capital LLC lifted its position in shares of Biogen by 31.2% in the first quarter. Quent Capital LLC now owns 391 shares of the biotechnology company's stock worth $54,000 after purchasing an additional 93 shares in the last quarter. Finally, CVA Family Office LLC boosted its holdings in Biogen by 71.1% during the first quarter. CVA Family Office LLC now owns 231 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 96 shares during the last quarter. Institutional investors own 87.93% of the company's stock.

Biogen Price Performance

Biogen stock traded down $0.57 during mid-day trading on Friday, reaching $132.63. The company had a trading volume of 633,328 shares, compared to its average volume of 1,434,583. The business has a fifty day simple moving average of $126.65 and a 200 day simple moving average of $134.69. The company has a market cap of $19.43 billion, a P/E ratio of 13.09, a P/E/G ratio of 1.06 and a beta of 0.14. The company has a current ratio of 1.44, a quick ratio of 1.01 and a debt-to-equity ratio of 0.27. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $238.00.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share for the quarter, missing analysts' consensus estimates of $3.26 by ($0.24). The firm had revenue of $2.43 billion for the quarter, compared to the consensus estimate of $2.25 billion. Biogen had a return on equity of 14.03% and a net margin of 15.07%. The company's revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.67 EPS. On average, equities research analysts predict that Biogen Inc. will post 15.83 earnings per share for the current year.

Analyst Ratings Changes

BIIB has been the topic of several recent research reports. Royal Bank Of Canada set a $213.00 price target on shares of Biogen and gave the company an "outperform" rating in a research note on Wednesday, June 25th. Hsbc Global Res downgraded shares of Biogen from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Robert W. Baird lowered their target price on Biogen from $300.00 to $255.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Oppenheimer set a $205.00 price target on Biogen in a report on Friday, May 2nd. Finally, Truist Financial decreased their price objective on Biogen from $210.00 to $199.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Twenty investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $188.48.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.